Product name as reported
Liraglutide Flexpen: adverse event reports filed with FDA
575 reports list it as a suspect or interacting product, 2010–2021.
- 575
- reports as suspect product
- 0% of all reports · about 35 a year
- 0
- reports, 12 months to June 2026
- 0 in the 12 months before
- 92.5%
- marked serious by the reporter
- 57.4% across all reports
- 8%
- record death among outcomes, as reported
- 46 reports · not verified by FDA
575 adverse event reports received by FDA list the product name "Liraglutide Flexpen" as reporters wrote it as a suspect or interacting product, from April 2010 to May 2021. A further 0 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 0 reports listed it, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 35 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded lipase increased (6.1%), cholelithiasis (4.3%) and nausea (3.7%). A report can list several reactions, so shares add to more than 100%; 94 different terms appear across these reports. Lipase increased is recorded in 6.1% of these reports, against 0% of all reports in the database.
92.5% of the reports are marked serious by the reporter; 8% record death among the outcomes and 68.2% record hospitalisation, as reported. 93.4% of the reports came from physicians, and the largest patient age group is 45 to 64 (38.3%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
No report listing Liraglutide Flexpen was received in the five years to June 2026; the latest was received in May 2021.
By year received
Reactions recorded in the reports
share of Liraglutide Flexpen reports recording the termall reports in the database
- Lipase increased6.1%35
- Cholelithiasisgallstones4.3%25
- Nauseafeeling sick3.7%21
- Abdominal painstomach or belly pain2.8%16
- Cholecystitis acute2.6%15
- Diarrhoealoose or frequent stools2.3%13
- Vomitingbeing sick2.1%12
- Coronary revascularisation1.9%11
- Angina unstable1.7%10
- Gastroenteritisstomach bug1.7%10
- Pancreatitisinflammation of the pancreas1.7%10
- Gastrooesophageal reflux diseaseacid reflux1.6%9
- Pneumonialung infection1.6%9
- Amylase increased1.4%8
- Atrial fibrillationan irregular heart rhythm1.4%8
- Cardiac failureheart failure1.4%8
- Cardiac failure congestivecongestive heart failure1.4%8
- Chest painchest pain1.2%7
- Abdominal pain upperupper stomach pain0.9%5
- Dizzinesslight-headedness or unsteadiness0.9%5
- Gastritisinflamed stomach lining0.9%5
- Pancreatic carcinoma0.9%5
- Cholecystitisinflamed gallbladder0.7%4
- Constipationconstipation0.7%4
- Decreased appetitereduced appetite0.7%4
- Diabetic ketoacidosisa serious complication of diabetes with acid build-up0.7%4
- Non-cardiac chest pain0.7%4
- Renal failure acute0.7%4
Top 30 of 94 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 25.2% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Type 2 diabetes mellitus | 395 | 68.7% |
| Obesity | 86 | 15% |
| Type 1 diabetes mellitus | 9 | 1.6% |
| Diabetes mellitus | 8 | 1.4% |
| Cardiac failure acute | 2 | 0.3% |
The indication field is filled in by the reporter and is often blank; shares are of all 575 reports.
In context
| Measure | Liraglutide Flexpen | All reports |
|---|---|---|
| Reports as suspect product | 575 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 92.5% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 80 | 91 |
| Hospitalisation recorded, per 1,000 reports | 682 | 213 |
| Consumer-filed share | 5.2% | 45.8% |
| Top term, share of reports | Lipase increased 6.1% | 0% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Liraglutide Flexpen reports
How many adverse event reports has FDA received for Liraglutide Flexpen?
575 reports list Liraglutide Flexpen as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 0 list it only as a concomitant medication.
What reactions are recorded in Liraglutide Flexpen reports?
lipase increased (6.1%), cholelithiasis (4.3%), nausea (3.7%), abdominal pain (2.8%) and cholecystitis acute (2.6%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Liraglutide Flexpen was responsible.
How serious are the reports?
92.5% are marked serious by the reporter. Among the outcomes recorded, 8% of reports include death and 68.2% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (93.4%), consumer or non-health professional (5.2%) and pharmacist (0.7%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Liraglutide Flexpen rising?
0 reports in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Liraglutide Flexpen was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Liraglutide Flexpen?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Liraglutide Flexpen as a suspect or interacting product; reports listing it only as a concomitant medication (0) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.